VYYRF (Voyageur Pharmaceuticals) YoY EBITDA Growth: -100.00% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYYRF Voyageur Pharmaceuticals Ltd VYYRF
28 GF Score
Price $0.08
! 6 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals YoY EBITDA Growth?

Voyageur Pharmaceuticals VYYRF -33.33% 28 YoY EBITDA Growth is -100.00% as of May. 2026. GuruFocus rates VYYRF with a GF Score™ of 28/100. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Voyageur Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in May. 2026 was -100.00%.

Voyageur Pharmaceuticals's EBITDA per Share for the three months ended in May. 2026 was $-0.00.

Voyageur Pharmaceuticals YoY EBITDA Growth Related Terms

Voyageur Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals YoY EBITDA Growth Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.67 29.41 33.33 -12.50 -66.67

Voyageur Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.33 -200.00 -50.00 25.00 -100.00
VYYRF
28GF Score
Voyageur Pharmaceuticals Ltd VYYRF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Voyageur Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Nov. 2025 is calculated as:

YoY EBITDA Growth (A: Nov. 2025 )
=(EBITDA per Share (A: Nov. 2025 )-EBITDA per Share (A: Nov. 2024 ))/ | EBITDA per Share (A: Nov. 2024 ) |
=(-0.015--0.009)/ | -0.009 |
=-66.67 %

Voyageur Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in May. 2026 is calculated as:

YoY EBITDA Growth (Q: May. 2026 )
=(EBITDA per Share (Q: May. 2026 )-EBITDA per Share (Q: May. 2025 )) / | EBITDA per Share (Q: May. 2025 )) |
=(-0.004--0.002)/ | -0.002 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -100.00% mean?
Voyageur Pharmaceuticals (VYYRF) has a YoY EBITDA Growth of -100.00% as of May. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Voyageur Pharmaceuticals and its competitors.
Is Voyageur Pharmaceuticals' YoY EBITDA Growth too high?
Voyageur Pharmaceuticals' current YoY EBITDA Growth is -100.00%. Overall, Voyageur Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' YoY EBITDA Growth compare to ZTS?
Voyageur Pharmaceuticals' YoY EBITDA Growth of -100.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Voyageur Pharmaceuticals and its competitors. Voyageur Pharmaceuticals's current YoY EBITDA Growth is -100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current YoY EBITDA Growth of -100.00%. The current YoY EBITDA Growth is -100.00%. Voyageur Pharmaceuticals' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current YoY EBITDA Growth is -100.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
28GF Score

Get the complete analysis for VYYRF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price